<DOC>
	<DOCNO>NCT00645736</DOCNO>
	<brief_summary>This study aim describe viral mutation profile patient diagnose chronic hepatitis B receive antihepadnaviral therapy .</brief_summary>
	<brief_title>CHARM : Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study</brief_title>
	<detailed_description>This naturalistic cross-sectional study chronic hepatitis B subject receive nucleoside nucleotide antihepadnaviral therapy . It anticipate approximately 800 subject recruit 20 Australian site . Data collect study subject analyse performed describe factor contribute emergence viral mutation Australian patient chronic hepatitis B .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Aged 18 year Provided informed consent Diagnosis chronic hepatitis B ( HBsAg document least 6 month ) Currently prescribe antihepadnaviral therapy ( include , limited : lamivudine , adefovir , entecavir , tenofovir telbivudine ) chronic hepatitis B management Been take current antihepadnaviral therapy least 6 month prior recruitment Negative test HIV Ab , Hepatitis C Ab Hepatitis D Ab within previous 2 year Known suspected coinfection HIV , Hepatitis C Hepatitis D Concomitant immunosuppression / immunomodulatory therapy Diagnosis hepatocellular carcinoma anticipate life expectancy le 6 month Current participation interventional , blind , pharmaceutical industrysponsored clinical trial Current Child Pugh class C classification ( current Child Pugh score &gt; 9 ) Other know suspect cause chronic liver disease Any reason , investigator 's opinion , participation study would participant 's best interest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>